
Correction to our earlier post: Wymer, Lehner et al. found HoLEP was most cost-effective for BPH in 30–80 and 80–150 cc prostates using a decision model. Patient preferences may change rankings. @vidit_sharma_ @SocietyofBPD doi.org/10.1016/j.urology.20…



